H. Michael Shepard
 |
H. Michael Shepard is an American cancer researcher.
He holds a bachelor's degree from the University of California, Davis. He received a Ph.D. from the Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP) to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab (trade name: Herceptin).
Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.
Dr. Shepard holds over 25 US patents.
Patents
- U.S. patent 7,138,388 — Methods to treat autoimmune and inflammatory conditions
- U.S. patent 7,105,156 — Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
- U.S. patent 6,946,259 — Compositions and methods for treating cells having double minute DNA
- U.S. patent 6,683,061 — Enzyme catalyzed therapeutic activation
- U.S. patent 6,551,585 — Use of tumor necrosis factor as an adjuvant
- U.S. patent 6,495,553 — Methods and compositions for overcoming resistance to biologic and chemotherapy
- U.S. patent 6,399,063 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 6,387,371 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 6,348,352 — Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
- U.S. patent 6,339,151 — Enzyme catalyzed therapeutic agents
- U.S. patent 6,333,169 — HER2 extracellular domain
- U.S. patent 6,331,524 — Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
- U.S. patent 6,245,750 — Enzyme catalyzed therapeutic agents
- U.S. patent 6,165,464 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 6,159,706 — Application of enzyme prodrugs as anti-infective agents
- U.S. patent 6,015,567 — HER2 extracellular domain
- U.S. patent 5,851,991 — Therapeutic use of the retinoblastoma susceptibility gene product
- U.S. patent 5,837,520 — Method of purification of viral vectors
- U.S. patent 5,772,997 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 5,720,954 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 5,710,255 — Characterization of a novel anti-p110.sup.RB monoclonal antibody
- U.S. patent 5,677,171 — Monoclonal antibodies directed to the HER2 receptor
- U.S. patent 4,963,354 — Use of tumor necrosis factor (TNF) as an adjuvant
- U.S. patent 4,808,402 — Method and compositions for modulating neovascularization